Health care stocks were steady premarket Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was slightly lower recently.
Alnylam Pharmaceuticals (ALNY) shares rose past 4% after the company said the US Food and Drug Administration has approved the supplemental new drug application for its heart drug Amvuttra.
Telix Pharmaceuticals (TLX) shares advanced nearly 4% after the company said the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.
Dyne Therapeutics (DYN) appointed Erick Lucera as chief financial officer, effective March 31. Dyne Therapeutics shares were nearly 7% lower pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.